Medical Editor: John P. Cunha, DO, FACOEP
Eucrisa (crisaborole) ointment, 2%, for topical use is a phosphodiesterase 4 inhibitor indicated for topical treatment of mild to moderate atopic dermatitis in patients 2 years of age and older. Common side effects of Eucrisa include application site pain.
Apply a thin layer dose of Eucrisa twice daily to affected areas. Eucrisa may interact with other drugs. Tell your doctor all medications and supplements you use. Tell your doctor if you are pregnant or plan to become pregnant before using Eucrisa; it is unknown if it would affect a fetus. It is unknown if Eucrisa passes into breast milk or how it will affect a nursing infant. Consult your doctor before breastfeeding.
Our Eucrisa (crisaborole) ointment, 2%, for topical use Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
SLIDESHOW
Rosacea, Acne, Shingles, Covid-19 Rashes: Common Adult Skin Diseases See Slideshow
SIDE EFFECTS
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
In two double-blind, vehicle-controlled clinical trials (Trial 1 and Trial 2), 1012 subjects 2 to 79 years of age with mild to moderate atopic dermatitis were treated with EUCRISA twice daily for 4 weeks. The adverse reaction reported by ≥ 1% of EUCRISA-treated subjects is listed in Table 1.
Table 1: Adverse Reaction
Occurring in ≥ 1% of Subjects in Atopic Dermatitis Trials through Week 4
| Adverse Reaction | EUCRISA N=1012 n (%) |
Vehicle N=499 n (%) |
| Application site paina | 45 (4) | 6 (1) |
| a Refers to skin sensations such as burning or stinging. | ||
Less common ( < 1%) adverse reactions in subjects treated with EUCRISA included contact urticaria [see WARNINGS AND PRECAUTIONS].
Read the entire FDA prescribing information for Eucrisa (crisaborole)
